Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

New £100 Million Fund to Capitalise on AI’s Game-Changing Potential in Life Sciences and Healthcare

A new mission announced by the Prime Minister will accelerate the use of AI in life sciences to tackle the biggest health challenges of our generation.

30 Oct 2023

Revolutionizing Drug Discovery: The Role of AI in Lead Optimization

Lead optimization in the field of drug discovery poses a formidable challenge, predominantly hinging on conjectures and the expertise of medicinal chemists.

25 Oct 2023

BioLizard Launches New AI-Empowered “BioVerse” Platform to Facilitate Data-Driven R&D for Global Life Sciences Community

BioLizard, the bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry, today announced the launch of its new BioVerse platform.

11 Oct 2023

Targeted MicroRNA-34a Therapy Shows Promise in Slowing Tumor Growth in Mice

A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division.

5 Sep 2023

Scale Biosciences Continues Commercial Expansion with Introduction of New and Differentiated Single Cell Methylation and Single Cell RNA Sequencing Solutions

Scale Biosciences, Inc. (ScaleBioTM), an innovator in single cell sequencing leveraging combinatorial indexing technologies, today announced an expansion of their product portfolio to enable a broader range of single cell omics experiments and unlock new translational research applications.

30 Aug 2023

Study Identifies 39 Genetic Mutations Associated With Heart Failure

In a new study co-led by investigators at the United States Department of Veterans Affairs and Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, a global team of scientists conducted one of the largest genetic association studies on heart failure to date.

25 Aug 2023

Innovative Method Accelerates Discovery of New Drugs by Harnessing the Power of Ribosomes

A research team led by University of California, Irvine scientists has developed an innovative method for quickly and efficiently creating vast collections of chemical compounds used in drug discovery by harnessing the power of ribosomes, the molecules found in all cells that synthesize proteins and peptides.

24 Aug 2023

From Neanderthals to New Drugs: Unlocking Ancient Proteins

We need to think big in antibiotics research.

17 Aug 2023

Discovering Age and Sex-Specific Obesity Genes in the Genome

Right from impacting how the human body stores fat to how the brain regulates appetite, hundreds of genes, together with environmental factors, jointly identify weight and body size.

3 Aug 2023

New Breakthrough in Generative AI Models and AlphaFold Structures for Drug Discovery

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple generative AI models and AlphaFold structures for drug discovery.

3 Aug 2023

Whitespotted Eagle Rays Have a Broader Diet Than Previously Thought

With mighty jaws and plate-like teeth, the whitespotted eagle ray (Aetobatus narinari) can pretty much crunch on anything.

2 Aug 2023

New Collaboration Aims to Advance Cancer Therapies Against Previously Undruggable Targets

The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns the innovative technology and capabilities of each organization at the earliest stages of drug discovery and development to rapidly advance impactful new cancer therapies against previously undruggable targets.

26 Jul 2023

Bioprocessing Breakthrough: Xheme Non-Toxic, Multifunctional Additive Eliminates Oxidative Stress

Oxidative stress, caused by an imbalance of free radicals and antioxidants, regularly reduces the yield of pharmaceuticals and therapeutics produced via bioprocessing by about 10-15%. Now, Xheme, Inc.'s Xheme Multifunctional Additive (XMA), a programmable non-toxic nanoporous microparticle, has demonstrated the ability to significantly reduce or eliminate the damage of oxidative stress in bioprocessing conditions.

25 Jul 2023

Unraveling the Link Between High Body Temperature and Increased Viral Resistance

Researchers from The University of Tokyo unravel the connection between high body temperature and increased viral resistance.

21 Jul 2023

Researchers Make Breakthrough in Fight Against Familial Hypercholesterolemia

The Mona Lisa, painted by the Italian artist Leonardo da Vinci, is one of the most recognizable paintings in the world.

21 Jul 2023

Uncovering New Insights into Virus Self-Assembly

Griffith University researchers were instrumental in controlling the way viruses are assembled by using DNA “origami” templates.

18 Jul 2023

Scientists Discover Specific Genes Involved in Rare, Life-Threatening Heart Disease

By identifying genes in patients and testing their effects in fruit flies, researchers from Sanford Burnham Prebys have found new genes that contribute to hypoplastic left heart syndrome (HLHS), a rare, life-threatening heart disease that occurs in infants.

18 Jul 2023

Next Step in Sartorius Partnership Finalized: Several Subsales and Distribution Agreements as Well as R&D Project Agreements Have Been Signed

During May and June 2023 several sub-sales and distribution agreements were signed between Sartorius and BICO companies CELLINK, Advanced BioMatrix (ABM) and Dispendix.

From BICO 5 Jul 2023

Deep Learning Model Accurately Predicts RNA-Targeting CRISPR Activity

According to new research published in Nature Biotechnology, artificial intelligence can predict on- and off-target behavior of CRISPR tools that target RNA rather than DNA.

5 Jul 2023

Camena Bioscience Closes $10m Series A Financing as Demand for DNA Synthesis Technology Increases

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has closed a $10m Series A financing round, led by Mercia.

4 Jul 2023